MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress » Huntington's Disease

Meeting: 2022 International Congress

A randomized, sham-controlled, crossover trial on Transcranial pulsed current stimulation (tPCS) in Huntington disease

M. Tuesta Bernaola, Y. Tamilselvam, Y. Mahdi, J. Ganguly, D. Aur, M. Jog (London, Canada)

A Useful Cognitive-Motor Dual Task Paradigm in Prodromal and Manifest HD

EG. Churchill, J. Corey-Bloom, A. Hall, C. Snell, A. Smirnova, SB. Hughes, PE. Gilbert, DJ. Goble (San Diego, USA)

All that emerge is not Lupus

M. Spitz, S. de Souza, I. Sodré, B. Panichelli (Rio de Janeiro, Brazil)

Analysis of Depression and Suicidality Throughout the Course of Huntington Disease Using the Enroll-HD Registry

S. Reshef, E. Furr Stimming, V. Sung, R. Willock, R. Ribalov, S. Brighton, S. Leo (Parsippany, USA)

Analyzing early states of HD progression using a machine learning driven approach

E. Eyigoz, S. Sathe, J. Warner, S. Dey, T. Li, P. Rojas, C. Sampaio, J. Hu (Yorktown Heights, USA)

Anosognosia in HD: Comparison of Self-report and Caregiver Ratings with Objective Performance Measures

SB. Hughes, A. Smirnova, A. Hall, C. Snell, B. Wright, PE. Gilbert, J. Corey-Bloom (San Diego, USA)

Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity

V. Sung, E. Furr Stimming, S. Reshef, R. Willock, R. Ribalov, S. Brighton, S. Leo (Birmingham, USA)

Cannabis treatment in patients with Huntington’s disease in a clinic cohort was safe and effective

N. Omer, A. Bar David, N. Geva, Y. Zlotnik, T. Gurevich, S. Essa (Tel-Aviv, Israel)

Cerebellar and other motor symptoms in Huntington’s Disease: A multiple scale correlation study

D. López-Mena, H. Martinez-Hernandez, J. Arista-Ramírez (Ciudad de Mexico, Mexico)

Cerebellar and other motor symptoms relationship with MRI features in Huntington disease.

H. Martinez-Hernandez, D. Lopez-Mena, A. Medina-Islas, L. Alvarez, I. Acosta (Mexico City, Mexico)

Chorea Severity Change Over Time in Huntington Disease and by Huntington Disease Stage

E. Furr Stimming, V. Sung, S. Reshef, R. Willock, R. Ribalov, S. Brighton, S. Leo (Houston, USA)

Clinical and biomarker characteristics of Huntington’s Disease patients recently proposed for huntingtin-lowering clinical trial inclusion

G. Parkin, E. Thomas, C. Snell, A. Smirnova, A. Hall, L. Bohall, E. Churchill, J. Corey-Bloom (Irvine, USA)

Cognition in Huntington’s Disease

A. Sethi, O. Kaczmarek, S. Baek, B. Bumstead, M. Buhse, M. Zarif, M. Gudesblatt (Patchogue, USA)

Cognitive profiling in a cohort of Huntington’s disease (HD) patients

M. Garon, F. Pistonesi, L. Weis, V. Cianci, T. Gandolfi, E. Fiorenzato, C. Tedesco, M. Campagnolo, M. Carecchio, A. Antonini, R. Biundo (Padua, Italy)

Comorbidities in Huntington’s disease: An Enroll-HD analysis

J. Mills, J. Long, J. Vaidya, C. Sampaio, S. Sathe (Iowa City, USA)

Contemporary study of the difficulties of late diagnostics in patients with Huntington’s disease in Uzbekistan

G. Goyibova, S. Kuranbaeva, A. Umarov, S. Kalandarova (Tashkent, Uzbekistan)

Defining minimal clinically important differences in Huntington’s disease: An anchor-based approach

J. Hamilton, J. Mills, G. Stebbins, J. Long, R. Fuller, S. Sathe, M. Roche, C. Sampaio (Princeton, USA)

Differences in cognition and neuropsychiatric profiles between asymptomatic and symptomatic carriers of Huntington’s disease

M. Turuelo (Barakaldo, Spain)

Feasibility of using ENROLL-HD for health services research: Evaluation of delays in Huntington’s Disease (HD) Diagnosis

A. Mendizabal, S. Perlman, Y. Bordelon (LOS ANGELES, USA)

How much do motor and non-motor symptoms of Huntington’s disease influence energy balance? BEHD-EM Pilot Study.

C. Collazo, E. Cubo, L. Simón, J. Rivadeneyra, A. Rodríguez, J. Raya, D. Castillo, M. Soto (Burgos, Spain)

Juvenile Huntington’s Disease in Tunisia: Clinical Diversity and Literature review

H. Nehdi, E. Chebbi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease

M. Gordon, D. Stamler, J. Savola, N. Gross, H. Barkay, M. Chen, N. Chaijale (West Chester, USA)

Olfactory dysfunction in patients with Huntington disease

J. Patino, H. Coco, S. Zadegan, S. Chandra, N. Karagas, N. Rocha, K. Anderson, A. Teixeira, E. Furr Stimming (Houston, USA)

Perceptions of Palliative Care in Huntington’s Disease

B. Heffernan, L. Seeberger, E. Forbes, J. Shattuck, M. Cook, R. Ayele (Aurora, USA)

Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)

R. Kumar, D. Claassen, A. Mongan, A. Grover, B. Hoehn, P. Lin, R. Arnold, E. Cahir-Mcfarland, T. Yednock, S. Keswani (Englewood, USA)

Profile and neural correlates of language disintegration in early Huntington’s disease

S. Martinez-Horta, A. Puig-Davi, F. Sampedro, J. Perez-Perez, J. Matias-Guiu, A. Horta-Barba, J. Pagonabarraga, M. Diez-Cirarda, L. Fernandez-Romero, M. Yus, F. Cuetos, J. Kulisevsky (Barcelona, Spain)

Real-World Treatment Patterns and Outcomes in Patients With Chorea Associated With Huntington Disease Using Tetrabenazine or Deutetrabenazine in Combination with Antipsychotic Drugs

D. Claassen, H. Romdhani, R. Ayyagari, D. Goldschmidt, S. Zoye Moroz, A. Hernandez, S. Leo (Nashville, USA)

Speech markers of Presymptomatic and Prodromal Huntington’s disease

A. Vogel, C. Chan, G. Stuart, P. Maruff, Y. Lie, J. Stout (Melbourne, Australia)

Structural and metabolic brain correlates of arithmetic word-problem solving in Huntington´s disease

A. Horta-Barba, S. Martinez-Horta, F. Sampedro, J. Perez-Perez, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit

K. Anderson, M. Konings, S. Finkbeiner, A. Cutler (Washington, USA)

VALIDATING ACCELEROMETRY AS A MEASURE OF ENERGY EXPENDITURE AND PHYSICAL ACTIVITY IN ADULTS WITH HUNTINGTON’S DISEASE

L. Simón, E. Cubo, J. Rivadeneyra, C. Collazo, M. Soto, J. Raya, D. Castillo, S. Calvo, A. Fernández (Burgos, Spain)

« View all sessions from the 2022 International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley